On June 18, 2026, Anhui Poly Pharm Co., Ltd. organized a highly informative special training session on the "Contract Review Pitfall Avoidance Guide." The company's legal advisory team was specially invited to explain the "law" on site, providing a systematic and in-depth presentation and analysis covering the definition and legal essence of contracts, the composition of core contract elements, contract review processes and key points, as well as typical cases combined with the company's actual business scenarios, helping all employees enhance their awareness of contract risk prevention and practical capabilities.
June 2026 marks the 25th National "Work Safety Month." In order to thoroughly implement the spirit of the theme "Everyone Talks About Safety, Everyone Knows Emergency Response," Anhui Poly Pharm Co., Ltd. carefully organized a series of diverse safety publicity and emergency drill activities, effectively enhancing the safety awareness and emergency response capabilities of all employees.
"The 24th World Pharmaceutical Ingredients China Exhibition" & "The 19th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition" (CPHI & PMEC China 2026) will be grandly held from June 16–18 at the Shanghai New International Expo Centre. We sincerely invite you to visit our booth! W1E26 — See you there!
Recently, Anhui poly Pharm Co., Ltd. (hereinafter referred to as "Anhui Primes") has made significant progress in the field of Boron Neutron Capture Therapy (BNCT). The Boron [¹⁰B] Melphalan (Borofalan ([¹⁰B])) API successfully completed its Drug Master File (DMF) submission to the U.S. Food and Drug Administration (hereinafter referred to as "FDA") on May 15, 2026.
From April 6 to 10, 2026, an expert team from the Brazilian Health Regulatory Agency (ANVISA) carried out a five-day official GMP on-site audit at Anhui Poly Pharmaceutical Co., Ltd. The audit was initially focused on the company's API product Sodium Nitroprusside, but during the process, the expert panel added an inspection of Voriconazole. This represents yet another successful comprehensive review by a globally recognized stringent drug regulatory authority, following the company's earlier certifications from China's NMPA and the U.S. FDA.
